Nkarta, Inc.
NKTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeNkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. At a $128.2M market cap, Nkarta, Inc. ranks as a micro-cap company within healthcare. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Market Cap
$128.2M
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-1.02
EPS (TTM)
$-1.58
EPS (Fwd)
$-1.75
ROE
-38.8%
ROA
-19.6%
Cash
$182.8M
Total Debt
$73.5M
Free CF
-$55.1M
52W Change
-23.8%
Annual Financials
Cash vs Debt
Where NKTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NKTX finished 33.71% below its 150-day moving average ($2.64) and 31.37% below its 200-day moving average ($2.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NKTX overbought or oversold?
At the October 20, 2026 close, NKTX's RSI(14) was 4.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $182.8M in cash and $73.5M in debt, NKTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$55.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -38.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, NKTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NKTX.